Active	Status	Sponsor type	Region	Phase	Filter
11 Active 4 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rowe, Dominic
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis	Recruiting	3	390	Europe, RoW	Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo	Macquarie University, Australia, King's College London, Stichting TRICALS Foundation	Amyotrophic Lateral Sclerosis	12/25	07/26
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation	Recruiting	3	150	Europe, Canada, Japan, US, RoW	Tofersen, BIIB067, QALSODY, Placebo	Biogen	Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation	08/27	08/27
REAL, NCT05218668: Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis	Active, not recruiting	2a	30	US, RoW	Fasudil (WP-0512)	Woolsey Pharmaceuticals	Amyotrophic Lateral Sclerosis	07/23	07/24
ACTRN12621000864820: 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)	Completed	2	16			Macquarie University, Macquarie University	Amyotrophic Lateral Sclerosis, Motor Neuron Disease
NCT03136809: ALS Treatment Extension Study	Active, not recruiting	1/2	28	RoW	Cu(II)ATSM, diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)	Collaborative Medicinal Development Pty Limited	Amyotrophic Lateral Sclerosis	12/22	12/22
NCT04894240: A Study of Monepantel in Individuals With Motor Neurone Disease	Completed	1	12	RoW	Monepantel	PharmAust Ltd, FightMND, Calvary Health Care Bethlehem, Macquarie University, Australia	Motor Neuron Disease	11/23	11/23
NCT06177431: An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease	Recruiting	1	12	RoW	Monepantel	PharmAust Ltd, Calvary Health Care Bethlehem, Macquarie University, Australia	Motor Neuron Disease	04/25	04/25
NCT05882695: Study of SPG302 in Healthy Volunteers and ALS Participants	Recruiting	1	112	US, RoW	SPG302, Placebo	Spinogenix, Novotech (Australia) Pty Limited	Amyotrophic Lateral Sclerosis	05/25	12/25
Kiernan, Matthew
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Terminated	3	486	Europe, Canada, US, RoW	Reldesemtiv, Placebo	Cytokinetics	Amyotrophic Lateral Sclerosis	07/23	07/23
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis	Recruiting	3	390	Europe, RoW	Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo	Macquarie University, Australia, King's College London, Stichting TRICALS Foundation	Amyotrophic Lateral Sclerosis	12/25	07/26
AMBALS, NCT05959850: A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS	Recruiting	2	50	RoW	Ambroxol, Ambroxol Hydrochloride, Placebo	The Florey Institute of Neuroscience and Mental Health, Mobius Medical Pty Ltd., The University of Queensland	Amyotrophic Lateral Sclerosis	06/24	12/24